← SynDRA
NEFLAMAPIMOD
SynDRA canonical compound SYN0004309 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | MAPK14 |
|---|
| Mechanism of action | P38 MAPK inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- MAPK14 INHIBITOR
- MAP kinase p38 alpha inhibitor
- MAPK11 INHIBITOR
- MAPK12 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- SRC
- LYN
- EPHA2
- EPHA4
- LCK
- BLK
- EPHA5
- EPHA8
- EPHB1
- SYK
- PDGFRB
- EPHB4
- PDGFRA
- ROS1
- FGR
- FRK
- FYN
- HCK
- SLC6A3
- EPHA1
- CSF1R
- ABCB11
- ABL1
- ABL2
- YES1
- MAPK13
- ADORA3
- DDR1
- NUAK2
- PAK2
- PAK1
- PKN2
- OXSR1
- OPRM1
- OPRK1
- OPRD1
- PIK3CD
- NUAK1
- PAK4
- NTRK3
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- VX-745
- 745
- NEFLAMAPIMOD (VX-745)
- VD-31
- VD-31,745
- VD-31745
- VRT-031745
- VX745
- VX 745
- 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one
- UNII-TYL52QM320
- TYL52QM320
- CHEBI:90528
- 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one
- 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one
- Neflamapimod (USAN)
- Neflamapimod [USAN]
- AK-44905
- C19H9Cl2F2N3OS
- 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One
- VX745, VX-745
- 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one
- Vertex 745 (VX745)
- neflamapimodum
- RefChem:832136
- MFCD09834070
- Kinome_3767
- Neflamapimod (USAN/INN)
- NEFLAMAPIMOD [INN]
- MLS006010281
- NEFLAMAPIMOD [WHO-DD]
- SCHEMBL156367
- GTPL5719
- orb1301083
- SCHEMBL29396525
- BDBM15244
- cid_3038525
- EX-A854
- GLXC-05950
Look up NEFLAMAPIMOD in the interactive SynDRA portal →